Streetbeat News

Marketing

BONKUSD

DOGEUSD

PEPEUSD

SHIBUSD

Bonk and Pepe, two meme coins, have seen significant weekly gains of 23.5% and 17.6% respectively, outperforming Dogecoin and Shiba Inu. The rally is attributed to Bitcoin's surge to $50,000. Bitstamp's listing of Pepe and bullish social media analysis further spotlight these coins. Despite their popularity, meme coins on the Solana network, like Bonk and Pepe, face volatility due to profit-taking. Dogwifhat, another Solana meme coin, has also seen an 80% weekly gain.

Portfolio Pulse from Khyathi Dalal

February 13, 2024 | 7:21 pm

CHGG

Traders are closely watching Chegg (CHGG) as it was mentioned in a popular retail stock newsletter, potentially influencing its stock price.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 6:06 pm

AMZN

PDD

WMT

Temu, a subsidiary of PDD Holdings Inc, is rapidly growing in the U.S. e-commerce market, challenging giants like Amazon and Walmart with its innovative Next-Generation Manufacturing (NGM) and aggressive marketing strategies, including a $14 million Super Bowl ad and over $200 million in PPC ads. Temu's focus on affordable luxury and efficient spending has led to significant growth, boasting 172 million app users and 43 million web visitors in just 12 months.

Portfolio Pulse from Surbhi Jain

February 13, 2024 | 4:38 pm

SPY

Director of the National Economic Council, Brainard, highlighted the ongoing issue of 'shrinkflation' affecting consumers, as reported by CNBC. Shrinkflation refers to the practice where companies reduce the size or quantity of their products while maintaining the same price, effectively raising the cost per unit for consumers.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 4:27 pm

CYTK

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its participation in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, scheduled for February 13, 2024. The event will feature Robert I. Blum, President and CEO, and can be accessed via the company's website. Following the event, a replay will be available for 90 days.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 4:15 pm

AMZN

MSFT

PLTR

Palantir Technologies Inc (NYSE:PLTR) reported Q4 earnings, surpassing estimates with a 20% YoY revenue increase to $608.4 million, driven by strong AI demand. Unlike its big tech counterparts like Microsoft (NASDAQ:MSFT) and Amazon.com Inc (NASDAQ:AMZN), which invested billions in AI, Palantir grew its customer base by 35% through unique marketing strategies like hosting 'boot camps'. This approach, along with a shift towards the private sector, has significantly contributed to its success, sending its stock soaring by approximately 50% post-earnings announcement.

Portfolio Pulse from Upwallstreet

February 13, 2024 | 4:06 pm

On CNBC, Coca-Cola Company's CEO James Quincey discussed the current demand for Coca-Cola products and the company's operations in the Middle East.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 3:24 pm

AAPL

NVDA

TSLA

Bitcoin, Ethereum, and Dogecoin rally, with Bitcoin surpassing $50K and predictions of reaching $130K. Stellantis adopts Tesla's charging standard, NACS. Various tech and EV companies face challenges and developments, including Apple, Nvidia, and Tesla. Financial markets anticipate inflation data, and geopolitical tensions are highlighted. In the crypto space, significant investments and activities are noted, alongside regulatory and market movements.

Portfolio Pulse from Akanksha Bakshi

February 13, 2024 | 2:21 pm

MASI

Masimo (NASDAQ:MASI) announced FDA clearance for its MightySat Medical, the first and only FDA-cleared medical fingertip pulse oximeter available OTC without a prescription. This device, powered by Masimo SET pulse oximetry technology, offers accurate and reliable oxygen saturation and pulse rate measurements for consumers and is now available for purchase online and will soon be in retail and drug stores. The FDA clearance distinguishes MightySat Medical from other non-FDA cleared pulse oximeters, providing consumers and healthcare providers with a trusted option for home monitoring.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 2:07 pm

NURO

NeuroMetrix, Inc. (NASDAQ:NURO) is reviewing strategic options to enhance the growth of its Quell neuromodulation and DPNCheck neurodiagnostic businesses, aiming to maximize shareholder value. Options include marketing changes, asset acquisitions or sales, and potential mergers. Ladenburg Thalmann & Co. is advising in this process. No specific transaction or timeline is confirmed. The company aims to manage resources effectively while exploring growth opportunities, especially considering recent changes in Medicare Advantage risk adjustments.

Portfolio Pulse from Benzinga Newsdesk

February 13, 2024 | 2:03 pm